Efficacy News and Research

RSS

Tumor texture analysis has prognostic potential

Tumor texture analysis, determined by computed tomography, holds promise as a prognostic biomarker in patients with esophageal cancer, research indicates.

15 Feb 2013

Gedunin could help kill cancer cells

Scientists at the Georgia Regents University Cancer Center have identified an Indian plant, used for centuries to treat inflammation, fever and malaria, that could help kill cancer cells.

15 Feb 2013

BioAlliance Pharma to extend Validive phase II trial in head and neck cancer

BioAlliance Pharma SA, an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the extension of its phase II clinical trial with Validive in the United States in radio/chemotherapy-induced oral mucositis prevention in patients with head and neck cancer.

15 Feb 2013

Kitchen table health assessments improve outcomes of Medicare Advantage members

A study by Matrix Medical Network and MVP Heath Care indicates that Medicare Advantage members who receive "kitchen table" health assessments have improved outcomes, including fewer hospital admissions, lower cost of claims and a higher level of satisfaction with their health plans.

15 Feb 2013

Dompé initiates enrollment in rhNGF phase I/II REPARO study for neurotrophic keratitis

The first patient has been enrolled in the phase I/II REPARO study, the first international clinical trial evaluating the ophthalmological use of a topical solution of recombinant human Nerve Growth Factor (rhNGF) for the treatment of moderate to severe neurotrophic keratitis (NK).

15 Feb 2013

FDA committee recommends approval of Guerbet’s Dotarem NDA for adults and children

Guerbet, the contrast agent specialist for medical imaging, today announced that the Medical Imaging Drugs Advisory Committee to US Food and Drug Administration (FDA) has voted unanimously by votes of 17 to 0 to recommend that FDA approve the New Drug Application (NDA) for Dotarem (gadoterate meglumine) for adults, and for pediatric use for children two years of age and older.

15 Feb 2013

DNA repair mechanisms tied to reproductive aging

Age-related decline in the efficacy of DNA repair may underlie reproductive aging, say researchers.

14 Feb 2013

Nerve stimulation could stave off migraine attacks

Transcutaneous stimulation of the trigeminal nerve has shown promise as a treatment for migraine, according to results of a randomized controlled trial.

14 Feb 2013

Researchers ESTABLISH efficacy of tedizolid phosphate for skin infections

Results from the phase III ESTABLISH-1 study show that the new antibiotic tedizolid phosphate is noninferior to linezolid for the treatment of acute bacterial and skin structure infections.

14 Feb 2013

Rivaroxaban ruled out for extended thromboprophylaxis

The benefits of extended prophylactic anticoagulation with rivaroxaban in acutely ill hospital patients are outweighed by an increased bleeding risk, shows a study in The New England Journal of Medicine.

14 Feb 2013

New study reveals racial disparities in chronic pain management

Opioids are frequently prescribed for pain management in noncancer patients, but recommended clinical guidelines for monitoring effectiveness and signs of drug abuse are often not implemented. Alongside well-documented racial disparities in prescribing opioid medications for pain, researchers report racial differences in the use of recommended opioid monitoring and follow-up treatment practices.

14 Feb 2013

Combination of Methotrexat and Tofacitinib shows promise against rheumatoid arthritis

Together with colleagues from the international rheumatic diseases research community, scientists of the Charité - Universitätsmedizin Berlin have presented a new therapy approach for the treatment of rheumatoid arthritis (RA), a chronic form of joint inflammation.

14 Feb 2013

Researchers identify new way to influence the vital serotonin signaling system

An interdisciplinary team of researchers from the University of Texas Medical Branch at Galveston and the University of Houston has found a new way to influence the vital serotonin signaling system - possibly leading to more effective medications with fewer side effects.

14 Feb 2013

Computer-based cognitive/behavioral training program can benefit patients with fragile X

Researchers at the UC Davis MIND Institute will examine whether children and youth with fragile X syndrome can improve their working memory, cognition and behavior by using an online computer-based cognitive training program, through a new $1 million grant from The John Merck Fund.

14 Feb 2013

Link between Jagged-1 protein and bone formation

Researchers from the University of Pennsylvania School of Veterinary Medicine have discovered that a protein called Jagged-1 stimulates human stem cells to differentiate into bone-producing cells.

14 Feb 2013

DBS can lead to long-term improvement in patients with neuropathic pain

For many patients with difficult-to-treat neuropathic pain, deep brain stimulation (DBS) can lead to long-term improvement in pain scores and other outcomes, according to a study in the February issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

14 Feb 2013

Tivozanib overall survival results announced by AVEO and Astellas

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) announced overall survival (OS) for tivozanib, an investigational agent, from the Phase 3 TIVO-1 (TIvozanib Versus sOrafenib in 1st line advanced RCC) study in patients with advanced renal cell carcinoma (RCC). The final OS analysis, as specified by the protocol, shows a median OS of 28.8 months (95% confidence interval [CI]: 22.5–NA) for tivozanib versus a median OS of 29.3 months (95% CI: 29.3–NA) for the comparator arm, sorafenib.

13 Feb 2013